Structural and in vitro anti-tubercular activity study of (E)-N’-(2,6-dihydroxybenzylidene)nicotinohydrazide and some transition metal complexes

• Published in: Journal of the Iranian Chemical Society 2015-05, Vol.12 (5), p.815-829
• Main Authors: Ogunniran, Kehinde Olurotimi, Mesubi, Micheal Adediran, Raju, K. V. S. N., Narender, Tadigoppula
• Format: Article
• Language: English
• Subjects: Analytical Chemistry; Biochemistry; Chemistry; Chemistry and Materials Science; Inorganic Chemistry; Organic Chemistry; Original Paper; Physical Chemistry
• ISSN: 1735-207X; 1735-2428
• DOI: 10.1007/s13738-014-0544-1

A template condensation of 2,6-dihydroxybenzaldehyde with nicotinic hydrazide at 20 °C yielded a tridendate ligand with the formation of azomethine bond. The structure of the ligand, H 3 L 2 was confirmed with the use of analytical and spectroscopic analysis such as CHN analysis, ESI mass spectrum, FTIR, UV–visible spectrum and NMR techniques. The use of 2D NMR further confirmed the structure of the ligand. Also, five ligand–metal complexes were synthesized using different techniques. The physico-chemical properties of the complexes were determined with the use of melting point determination, conductivity test, micro-analysis, metal content determination (AAS), magnetic susceptibility measurements, FTIR, UV–visible spectra, ESR, TG/DTG and p- Xray diffraction study. The structures of the metal complexes were elucidated based on the analytical and spectroscopic data obtained. However, the anti-tubercular activities of the compounds were evaluated against H37Rv strain of Mycobacterium tuberculosis , in vitro. The results obtained indicated that the metal complexes are more active than isoniazid with MIC = 0.91 µg/mL. V(II) complex was found to be the most active with MIC of 0.62 µg/mL while Cu(II) complex with MIC values of 0.85 µg/mL is the least potent among the metal complexes synthesized. However, the results of the cytotoxicity against vero cells indicated that the metal complexes are more toxic when compared to the standard drug.